Legislative, educational, policy and other interventions targeting physicians’ interaction with pharmaceutical companies: a systematic review
Open accessAbstract
Background: Pharmaceutical company representatives likely influence the prescribing habits and professional behaviour of physicians. Objective: The objective of this study was to systematically review the effects of interventions targeting practising physicians’ interactions with pharmaceutical companies. Eligibility criteria: We included observational studies, non-randomised controlled trials (non-RCTs) and RCTs evaluating legislative, educational, policy or other interventions targeting the interactions between physicians and pharmaceutical companies. Data sources: The search strategy included an electronic search of MEDLINE and EMBASE. Two reviewers performed duplicate and independent study selection, data abstraction and assessment of risk of bias. Appraisal and synthesis methods: We assessed the risk of bias in each included study. We summarised the findings narratively because the nature of the data did not allow a meta-analysis to be conducted. We assessed the quality of evidence by outcome using the GRADE methodology. Results: Of 11 189 identified citations, one RCT and three observational studies met the eligibility criteria. All four studies specifically targeted one type of interaction with pharmaceutical companies, that is, interactions with drug representatives. The RCT provided moderate quality evidence of no effect of a ‘collaborative approach’ between the pharmaceutical industry and a health authority. The three observational studies provided low quality evidence suggesting a positive effect of policies aiming to reduce interaction between physicians and pharmaceutical companies (by restricting free samples, promotional material, and meetings with pharmaceutical company representatives) on prescription behaviour. Limitations: We identified too few studies to allow strong conclusions. Conclusions: Available evidence suggests a potential impact of policies aiming to reduce interaction between physicians and drug representatives on physicians’ prescription behaviour. We found no evidence concerning interventions affecting other types of interaction with pharmaceutical companies.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Policies and legislation regulating physician interactions with pharmaceutical representatives show substantial heterogeneity across countries.
“However, relevant policies and legislations show substan tial heterogeneity across countries [252][253][254][255] .”
From Ethical challenges in contemporary psychiatry: an overview and an appraisal of possible strategies and research needs (2024) · cites this paper as [253]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Dermyshi, E., Wang, Y., Yan, C., Hong, W., Qiu, G., Gong, X., & Zhang, T. (2017) · Neonatology · doi:10.1159/000454668 · Cited by 24,577 · see citing works
GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables
Guyatt, G., Oxman, A. D., Akl, E. A., Kunz, R., Vist, G., Brozek, J., Norris, S., Falck-Ytter, Y., Glasziou, P., & deBeer, H. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.04.026 · Cited by 10,681 · see citing works
Self-citationNorderyd, O. M., Koch, G., Papias, A., Köhler, A. A., Helkimo, A. N., Brahm, C., Lindmark, U., Lindfors, N., Mattsson, A., Rolander, B., et al. (2015) · PubMed · Cited by 3,584 · see citing works
Physicians and the Pharmaceutical Industry
Wazana, A. D. (2000) · JAMA · doi:10.1001/jama.283.3.373 · Cited by 1,418 · see citing works
Effect of antihypertensive samples on physician prescribing patterns.
Boltri, J. M., Gordon, E. R., & Vogel, R. L. (2003) · PubMed · Cited by 85 · see citing works
Grande, D. (2009) · Journal of General Internal Medicine · doi:10.1007/s11606-009-1016-7 · Cited by 83 · see citing works
Commercial detailing techniques used by pharmaceutical representatives to influence prescribing
Roughead, E. E., Harvey, K. J., & Gilbert, A. L. (1998) · Australian and New Zealand Journal of Medicine · doi:10.1111/j.1445-5994.1998.tb01953.x · Cited by 58 · see citing works
Othman, N., Vitry, A. I., Roughead, E. E., Ismail, S. B., & Omar, K. (2010) · BMC Public Health · doi:10.1186/1471-2458-10-743 · Cited by 44 · see citing works
Carroll, A. E., Vreeman, R., Buddenbaum, J. L., & Inui, T. S. (2007) · PEDIATRICS · doi:10.1542/peds.2007-0363 · Cited by 29 · see citing works
Everything you need to know about the Sunshine Act
Silverman, E. (2013) · BMJ · doi:10.1136/bmj.f4704 · Cited by 26 · see citing works
Effect of Drug Sample Removal on Prescribing in a Family Practice Clinic
Hartung, D. M., Evans, D., Haxby, D. G., Kraemer, D. F., Andeen, G., & Fagnan, L. J. (2010) · The Annals of Family Medicine · doi:10.1370/afm.1135 · Cited by 22 · see citing works
Do pharmaceutical representatives misuse their drug samples?
Tong, K. L., & Lien, C.-W. (1995) · PubMed · Cited by 15 · see citing works
Freemantle, N., Johnson, R. E., Dennis, J. A., Kennedy, A. D. M., & Marchment, M. (2000) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2000.00126.x · Cited by 13 · see citing works
General practitioners and pharmaceutical sales representatives: quality improvement research
Spurling, G., & Mansfield, P. R. (2007) · BMJ Quality & Safety · doi:10.1136/qshc.2006.020164 · Cited by 12 · see citing works
Controlling Quality in CME/CPD by Measuring and Illuminating Bias
Dixon, D., Takhar, J., Macnab, J. J., Eadie, J., Lockyer, J., Stenerson, H., François, J., Bell, M. J., Monette, C., Campbell, C., et al. (2011) · Journal of Continuing Education in the Health Professions · doi:10.1002/chp.20114 · Cited by 10 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Fadlallah, R., El‐Jardali, F., Hemadi, N., Morsi, R. Z., Samra, C. A., Ahmad, A., Arif, K., Hishi, L., Honein-AbouHaidar, G. N., & Akl, E. A. (2018) · International Journal for Equity in Health · doi:10.1186/s12939-018-0721-4 · Cited by 195 · see citing works
Self-citationBrax, H., Fadlallah, R., Alkhaled, L., Kahale, L. A., Nas, H., El‐Jardali, F., & Akl, E. A. (2017) · PLoS ONE · doi:10.1371/journal.pone.0175493 · Cited by 152 · see citing works
Self-citationPhysician Payments from Industry Are Associated with Greater Medicare Part D Prescribing Costs
Perlis, R. H., & Perlis, C. (2016) · PLoS ONE · doi:10.1371/journal.pone.0155474 · Cited by 115 · see citing works
Interventions to reduce corruption in the health sector
Gaitonde, R., Oxman, A. D., Okebukola, P. O., & Rada, G. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008856.pub2 · Cited by 117 · see citing works
Galderisi, S., Appelbaum, P. S., Gill, N., Gooding, P., Herrman, H., Melillo, A., Myrick, K., Pathare, S., Savage, M., Szmukler, G., et al. (2024) · World Psychiatry · doi:10.1002/wps.21230 · Cited by 76 · see citing works
Fadlallah, R., Nas, H., Naamani, D., El‐Jardali, F., Hammoura, I., Alkhaled, L., Brax, H., Kahale, L. A., & Akl, E. A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0160540 · Cited by 45 · see citing works
Self-citationEl‐Jardali, F., Fadlallah, R., Daouk, A., Rizk, R., Hemadi, N., Kebbi, O. E., Farha, A., & Akl, E. A. (2018) · The International Journal of Health Planning and Management · doi:10.1002/hpm.2625 · Cited by 33 · see citing works
Self-citationTorgerson, T., Wayant, C., Cosgrove, L., Akl, E. A., Checketts, J. X., Dal‐Ré, R., Gill, J., Grover, S. C., Khan, N. A., Khan, R., et al. (2020) · BMJ Evidence-Based Medicine · doi:10.1136/bmjebm-2020-111503 · Cited by 33 · see citing works
Self-citationLotfi, T., Morsi, R. Z., Rajabbik, M. H., Alkhaled, L., Kahale, L. A., Nass, H., Brax, H., Fadlallah, R., & Akl, E. A. (2016) · BMC Health Services Research · doi:10.1186/s12913-016-1299-4 · Cited by 31 · see citing works
Self-citationFadlallah, R., Alkhaled, L., Brax, H., Nasser, M., Rajabbik, M. H., Nass, H., Kahale, L. A., & Akl, E. A. (2018) · European Journal of Public Health · doi:10.1093/eurpub/ckx204 · Cited by 30 · see citing works
Self-citationZarei, E., Jolfayi, A. G., Nikoobar, A., Bastami, S., & Hamdghaddari, H. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2022.1072708 · Cited by 31 · see citing works
Ethical drug marketing criteria for the 21st century
Parker, L., Williams, J. H., & Bero, L. A. (2018) · BMJ · doi:10.1136/bmj.k1809 · Cited by 26 · see citing works
An evidence-based framework for identifying technologies of no or low-added value (NLVT)
Esandi, M. E., Gutiérrez‐Ibarluzea, I., Ibargoyen-Roteta, N., & Godman, B. (2019) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462319000734 · Cited by 17 · see citing works
Industry payments and physicians prescriptions: Effect of a payment restriction policy
Ansari, B. (2021) · Social Science & Medicine · doi:10.1016/j.socscimed.2021.113942 · Cited by 12 · see citing works
Ammous, A., Eddine, S. B. Z., Dani, A., Dbaibou, J., El‐Asmar, J. M., Sadder, L., & Akl, E. A. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-013041 · Cited by 11 · see citing works
Self-citationGPs’ perceptions of their relationship with the pharmaceutical industry: a qualitative study
Larkin, J., Pericin, I., Collins, M., Smith, S. M., Byrne, D., & Moriarty, F. (2021) · BJGP Open · doi:10.3399/bjgpo.2021.0057 · Cited by 8 · see citing works
A Critical Look at Innovation Profile and Its Relationship with Pharmaceutical Industry
Prata, R. G. S. W. M., Dias, C. Z., & Guerra, A. A. (2017) · International Journal of Scientific Research and Management (IJSRM) · doi:10.18535/ijsrm/v5i7.20 · Cited by 8 · see citing works
Gillani, A. H., Omer, S., Arshad, H., Liu, W., Chen, C., Bashir, S., Ahmed, A. B., Munir, A., Saeed, A., Bashir, K., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.787891 · Cited by 7 · see citing works
Finkel, K. J., Takata, E. T., Maffeo-Mitchell, C. L., Neal, J. B., Nankin, M., Braffett, B. H., Perillo, L. M., Gammerman, S., Stuart, W. T., & Walker, A. (2022) · British Journal of Anaesthesia · doi:10.1016/j.bja.2022.06.032 · Cited by 5 · see citing works
Pokorny, A. M. J., Bero, L. A., Fox, P., Karikios, D. J., McEwin, E. J., Moynihan, R. N., & Mintzes, B. J. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-065719 · Cited by 4 · see citing works
Teaching medical students how to interact with the pharmaceutical industry: A scoping review
Farah, S., & Bilszta, J. L. C. (2022) · PubMed Central · doi:10.3205/zma001578 · Cited by 4 · see citing works
Strategies for Management of Conflict of Interests in the Pharmaceutical Sector: A Systematic Review
Roknabadi, E. H., Vatankhah, S., Gorji, H. A., Behzadifar, M., & Aryankhesal, A. (2024) · Health Scope · doi:10.5812/healthscope-147134 · Cited by 3 · see citing works
Khan, M. S., Noor, M. N., Rahman-Shepherd, A., Siddiqui, A. R., Khan, S. S., van der Mark, N., Isani, A. K., Siddiqi, A. Q., Opondo, C., Ziauddin, F., et al. (2024) · BMJ Global Health · doi:10.1136/bmjgh-2024-016055 · Cited by 3 · see citing works
Noor, M. N., Rahman-Shepherd, A., Khan, S. S., Hasan, R., Siddiqui, A. R., Azam, I., Bhutto, F., Isani, A. K., Siddiqi, S., Khan, R. I., et al. (2024) · Journal of Health Services Research & Policy · doi:10.1177/13558196241230853 · Cited by 2 · see citing works
Lotfi, T., Morsi, R. Z., Zmeter, N., Godah, M. W., Alkhaled, L., Kahale, L. A., Nass, H., Brax, H., Fadlallah, R., & Akl, E. A. (2015) · BMC Research Notes · doi:10.1186/s13104-015-1709-4 · Cited by 2 · see citing works
Self-citationKhoo, E. J., & Chua, S. H. (2018) · Acta Paediatrica · doi:10.1111/apa.14362 · Cited by 2 · see citing works
Latif, A., Ansari, M. S., Ansari, M. I., Malik, R., Sohoo, A. A., Sohoo, F., & Zaib, U. (2021) · Pakistan Journal of Public Health · doi:10.32413/pjph.v11i1.284 · Cited by 2 · see citing works
Will the journal club survive?
MacLaren, T., & Warner, J. P. (2016) · BJPsych Advances · doi:10.1192/apt.bp.115.015479 · Cited by 1 · see citing works
Pharma Payments and Physician Concentration: An Empirical AnalysisPreprint
March, R. J. (2018) · SSRN Electronic Journal · doi:10.2139/ssrn.3188322
Evidencia sobre conflictos de intereses en medicina
Mariño, M. A. G. (2020) · Revista de la Facultad de Medicina · doi:10.15446/revfacmed.v68n1.73475
Salim, H. S., Lee, P. Y., Ching, S. M., Mawardi, M., Idris, W. N. A. W., & Harrun, N. H. (2023) · Malaysian Journal of Medicine and Health Sciences · doi:10.47836/mjmhs.19.s17.13
Pharmaceutical marketing and patient trust: How do doctor-targeted campaigns affect patients?
Makowska, M., Ozaki, A., & Ozierański, P. (2026) · PLoS ONE · doi:10.1371/journal.pone.0344509
- Authors
- Alkhaled, L., Kahale, L., Nass, H., Brax, H., Fadlallah, R., Badr, K., & Akl, E. A.
- Affiliations
- American University of Beirut (LB)
- Damascus University (SY)
- Saint Joseph University (LB)
- University at Buffalo, State University of New York (US)
- Corresponding author
- Akl, Elie A
- Venue
- BMJ Open
- Publisher
- BMJ
- Published
- 2014-07
- Volume
- 4
- Issue
- 7
- Pages
- e004880
- ISSN
- 2044-6055 (ISSN-L)
- PMC
- PMC4091460
- OpenAlex
- W2157721981
- Cited by
- 32
- References
- 15
- Citations by year
- 2026: 1 · 2024: 4 · 2023: 3 · 2022: 3 · 2021: 3 · 2020: 2 · 2019: 1 · 2018: 5 · 2017: 4 · 2016: 5 · 2015: 1
- FWCI
- 0.60
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- BMJ Open (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmaceutical industry and healthcare
- Social Sciences › Business, Management and Accounting › Organizational Behavior and Human Resource Management › Global Public Health Policies and Epidemiology
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Keywords
- physician-industry relations, pharmaceutical industry, pharmaceutical sales representatives, prescription behavior, pharmaceutical industry policy, free samples, promotional materials, legislative intervention, educational intervention, conflicts of interest
- MeSH terms
- Drug Industry, Interprofessional Relations, Physicians, Policy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
